Human Papillomavirus Vaccine against Cervical Cancer: New Usage Strategies and Coverage Issues

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 4462

Special Issue Editors


E-Mail Website
Guest Editor
Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60213 Ancona, Italy
Interests: pathology of the lower genital tract disease; HPV related disaese; HPV vaccination; HPV genotype distribution
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60213 Ancona, Italy
Interests: pathology of the lower genital tract disease; HPV related disease; HPV vaccination; HPV genotype distribution
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cervical cancer (CC) represents one of the most common female cancers worldwide, with 80% of cases originating from developing countries. These data are surprising given that CC is the only tumor that has primary and secondary prevention. The WHO has set goals for its elimination by 2030, proposing a vaccination coverage of 90%. In many countries worldwide, the vaccination coverage is well below this set goal. Hence, there is a need to implement vaccination coverage.

This Special Issue aims to provide evidence regarding the use of the HPV vaccine in different settings. Adolescent girls represent the primary target, but its use after excisional or definitive treatments is a trending topic of interest. Furthermore, the tools necessary for its implementation aimed at women of screening age or parents with daughters of vaccination age are topics of crucial interest.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: HPV vaccination coverage in developed and developing countries, HPV vaccination after conization, HPV vaccination after hysterectomy for cervical pathology, the role of HPV vaccination after fertility-sparing treatment, HPV vaccination in male, HPV vaccination in vaginal and vulvar pathology, and HPV genotype distribution in cervical pathology according to age.

We look forward to receiving your contributions.

Dr. Luca Giannella
Dr. Andrea Ciavattini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HPV vaccination coverage
  • HPV vaccination after conization
  • HPV vaccination in fertility-sparing treatment
  • male HPV vaccination HPV
  • vaccination after hysterectomy
  • tools for HPV vaccination implementation
  • HPV genotype in pre-invasive and invasive cervical pathology
  • HPV vaccination in vaginal pathology
  • HPV vaccination in vulvar pathology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 3340 KiB  
Article
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model
by Zhenwei Han, Shen Wang, Ting Mu, Ping Zhao, Lingli Song, Ying Zhang, Jin Zhao, Wen Yin, Yue Wu, Huan Wang, Bo Gong, Min Ji, Richard B. S. Roden, Yanping Yang, Michel Klein and Ke Wu
Vaccines 2024, 12(6), 689; https://doi.org/10.3390/vaccines12060689 - 20 Jun 2024
Viewed by 3825
Abstract
Human papillomavirus (HPV) is a prevalent cause of mucosal and cutaneous infections and underlying conditions ranging from benign warts to anogenital and oropharyngeal cancers affecting both males and females, notably cervical cancer. Cervical cancer is the fourth leading cause of cancer deaths among [...] Read more.
Human papillomavirus (HPV) is a prevalent cause of mucosal and cutaneous infections and underlying conditions ranging from benign warts to anogenital and oropharyngeal cancers affecting both males and females, notably cervical cancer. Cervical cancer is the fourth leading cause of cancer deaths among women globally and is the most impactful in low- and middle-income countries (LMICs), where the costs of screening and licensed L1-based HPV vaccines pose significant barriers to comprehensive administration. Additionally, the licensed L1-based HPV vaccines fail to protect against all oncogenic HPV types. This study generated three independent lots of an L2-based target antigen (LBTA), which was engineered from conserved linear L2-protective epitopes (aa11–88) from five human alphapapillomavirus genotypes in E. coli under cGMP conditions and adjuvanted with aluminum phosphate. Vaccination of rabbits with LBTA generated high neutralizing antibody titers against all 17 HPV types tested, surpassing the nine types covered by Gardasil®9. Passive transfer of naïve mice with LBTA antiserum revealed its capacity to confer protection against vaginal challenge with all 17 αHPV types tested. LBTA shows stability at room temperature over >1 month. Standard in vitro and in vivo toxicology studies suggest a promising safety profile. These findings suggest LBTA’s promise as a next-generation vaccine with comprehensive coverage aimed at reducing the economic and healthcare burden of cervical and other HPV+ cancers in LMICs, and it has received regulatory approval for a first-in-human clinical study (NCT05672966). Full article
Show Figures

Figure 1

Back to TopTop